ADR120S, Inc. (TYO:3750)

Market Cap	7.08B +20.3%
Revenue (ttm)	50.00M -59.0%
Net Income	-396.00M
EPS	-44.35
Shares Out	8.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,500
Open	788.00
Previous Close	793.00
Day's Range	784.00 - 801.00
52-Week Range	695.00 - 990.00
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About ADR120S

ADR120S, Inc. engages in the research, development, production, and sale of cell therapy related medical devices in Japan. The company sells cell therapy kits, as well as engages in the research and development of cell therapy technology, etc. Its products pipeline includes ECCI-50 for the treatment of male stress urinary incontinence; ECCL-50 to treat liver cirrhosis; and Cyt-006 to prevent postoperative adhesion for primary rectal cancer. The company is also conducting clinical trials/research on cell therapy for a range of diseases and appli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 10
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 3750

Financial Performance

In fiscal year 2026, ADR120S's revenue was 50.00 million, a decrease of -59.02% compared to the previous year's 122.00 million. Losses were -396.00 million, -81.50% less than in 2025.